UpdatesPlus-Nicotinic Receptors

LeadDiscovery
February 20, 2008
SKU: LD1692841
License type:
What's in the February 2008 edition of UpdatesPlus-Nicotinic Receptors

The February 2008 edition of UpdatesPlus-Nicotinic Receptors reports on key events identified through tracking of:
  • Journal Publications
  • Clinical Trials
  • Company Press Releases
  • Investor presentations
This month, as usual we provide a fully up to date snapshot of the nicotinic receptor ligand pipeline. In addition we report on breaking activity:
  • Memory Pharmaceuticals' phase 2a study of MEM 3454 in CIAS
  • Research activity from within Abbott researchers focussing on a novel series of á7 agonists
  • Movement from within Italian biotech, Siena toward the identification of nicotinic candidates
  • Breaking data to support the development of nicotinic receptor ligands as treatments of lung cancer
  • New efforts to validate varenicline (Chantix) as a candidate treatment of cocaine addiction Pfizer change label for Chantix in reponse to safety issues
  • A NeuroSearch pipeline update
  • Preclinical research describing the potential of ABT-894 as a treatment of visceral pain
Pricing & Delivery:
UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting

About UpdatesPlus:
Through DailyUpdates, LeadDiscovery has access to one of the most comprehensive sources of information for the drug development sector. UpdatesPlus takes this information and uses our industrial experience to provide a monthly analysis of breaking activity in selected indications and molecular targets. If this is the first time that you have heard of UpdatesPlus please take a moment to have a look at an example. If you would find such a service of use in your area contact us now.